cyrilzakka/clinical-trials huggingface dataset:
A Study on the Correlation Between Endometriosis and Intra-tissue Microbiota

Endometriosis (EM) is a common gynecological condition, but the pathogenesis of it has not yet been clarified. Here, the investigators wanted to investigate the correlation between endometriosis and the intra-tissue microbiota. The investigators planed to collect serum, vaginal swabs, cervical mucus, feces, peritoneal fluid, and endometrial tissue for sequencing and experiments.

Endometriosis (EM) is a common gynecological condition that occurs in women of reproductive age and is characterized by pain, masses, and infertility. EM is a tumor-like disease that is invasive, metastatic, recurrent, but the pathogenesis of EM has not yet been clarified. Advances in the study of intratumoral microbiota provided increasing evidence confirming the presence and mechanism of bacteria in tumor tissues. Therefore, the investigators wanted to investigate the correlation between endometriosis and its microbiota in the endometrial tissue.

Participants in this study will be recruited in the obstetrics and Obstetrics and Gynecology Medical Center of Zhujiang Hospital. With reference to the inclusion and exclusion criteria, patients admitted for surgery were under screening. Participants were assigned to Endometriosis group after confirmation by laparoscopy together with biopsy analysis, while the control group was identified as non-EM patients, usually with benign gynecologic conditions such as uterine fibroids or teratomas.

The investigators will obtain serum, vaginal swabs, cervical mucus, and feces from the participant before surgery. The peritoneal fluid, eutopic endometrium, and ectopic endometrium lesion will also be collected if the surgical approach allows. The specimens will be sent for microbiota sequencing, transcriptome sequencing, metabolome sequencing, single cell sequencing, and laboratory experiments.

Eligibility Criteria:
Inclusion Criteria:

1. Women aged 18-52 years old.
2. Regular menstruation with a cycle of 28-35 days.
3. No sexual intercourse 1 week before the operation.
4. No systemic or local use of antibiotics and probiotics for 6 months prior to surgery.
5. No history of acute or chronic pelvic inflammatory disease.
6. Subjects fully understand the significance of the study and sign the informed consent form.

Exclusion Criteria:

1. In pregnancy.
2. Intraoperative conditions or pathological examination suggest a malignant or junctional disease.
3. Severe anatomical abnormalities of the pelvis.
4. Pelvic contamination with large amounts of blood during laparoscopic operation.
5. History of gene therapy, blood transfusion, stem cell therapy, or bone marrow transplantation
6. Psychiatric, personality disorders, or abuse of psychoactive substances.
7. Immunodeficiencies, allergies, or autoimmune diseases.
8. Contraindications to endotracheal intubation anesthesia.
9. Absolute or relative contraindications to laparoscopic or hysteroscopic surgery.
A Clinical Study of Portal Vein Embolization and Liver Venous Deprivation

The main obstacle to achieving R0 resection in future liver remnant（FLR） deficient liver cancer is the inability to retain sufficient FLR to avoid postoperative liver failure. From the initial portal vein embolization(PVE), to the later ALPPS, this problem has been solved to some extent. However, both have their own shortcomings. The effect of liver hyperplasia after PVE is poor and the waiting time is long. The incidence of complication and mortality after ALPPS is always the focus of controversy. In recent years, LVD has emerged, combining PVE and HVE in the one operation. This topic will conduct a clinical controlled study of PVE and LVD.


Eligibility Criteria:
Inclusion Criteria:

* ① Age 18 to 75 years old, male or female.

  * hepatocellular liver cancer diagnosed by pathological histology, immunohistochemistry or imaging examination, with large tumor size that cannot be removed in one stage surgery

    * No distant metastasis of the lesion.

      * FLR\<20% in patients with normal liver function; FLR\<30% in patients with combined fatty liver and receiving chemotherapy; FLR\<40% in compensated cirrhosis ⑤ Normal function of major organs other than liver-related functions. ⑥ Subjects voluntarily enrolled in this study, signed informed consent, good compliance, and cooperated with follow-up.

        * Patients who the investigator believes can benefit.

Exclusion Criteria:

* Withdrawal of consent by the subject.

  * Having adverse reactions. ③ Failure to receive treatment due to progression.

    * Death of the patient.

      * Loss to follow-up. ⑥ Others.
The Role of Intracranial Electroencephalography (IEEG) in the Localization of Epileptogenic Zones (EZ) and Its Relationship With Prognosis

The mechanism of epilepsy pathogenesis is complex and not fully defined, and about 20-30% of patients with seizures that cannot be completely controlled by drugs become drug-resistant epilepsy. For focal drug-resistant epilepsy, surgical removal of the epileptogenic zone can control seizures, but the overall seizure-free rate in the long term after surgery is 60-70%, and the results are still not satisfactory. Accurate assessment of the location and extent of the epileptogenic zone and its adequate excision are prerequisites for the success or failure of surgery. Intracranial EEG (iEEG) has been shown to be the most accurate method for determining the location and boundaries of the epileptogenic zone. It can selectively record the local cortical electrical activity through intracranial electrodes and achieve high temporal resolution for long-range recording, reliably reflecting the continuous dynamic changes of EEG during interictal and ictal periods. The in-depth analysis of iEEG can improve the efficacy of epilepsy surgery and provide important information to reveal the pathogenesis of epilepsy.


Eligibility Criteria:
Inclusion Criteria:

1. Complete clinical history;
2. IEEG monitoring at least one habitual seizure；
3. Follow up for at least 1 year；
4. Signed informed consent.

Exclusion Criteria:

1. Habitual seizures were not found in iEEG monitoring;
2. No operation was performed;
3. Lost to follow-up for various reasons within 1 year after surgery.
Computed Tomography for Evaluating Supination-external Rotation Type Ankle Fractures

To compare measures of ankle stability from an investigational cone beam computed tomography scanner to gravity stress X-ray in patients who have unstable supination-external rotation ankle fractures.


Eligibility Criteria:
Inclusion Criteria:

* willing \& able to provide written informed consent
* at least 18 years-old
* have medial clear space measuring less than 5 mm with clinical suspicion of instability and would normally require a gravity stress X-ray

Exclusion Criteria:

* pregnant (females)
* prisoners
* open fracture
* clinical signs of foot deformity
* previous foot trauma or surgery on the affected foot
* significant osteoarthritis or pre-existing ligamentous instability or pain in the affected foot
* unable to stand in the weight bearing position during the CT scan
The Clinical Characteristics of the Patients With Choledocholithiasis Without Cholangitis

Laboratory change induced by common bile duct (CBD) stone is in general observed as the higher elevation of alkaline phosphatase (ALP) and gamma-glutamyl transpeptideas (ɤ-GT), in comparison to those of aspartate aminotransferase (AST) and alanine aminotransferase (ALT). However, some patients with CBD stone show the marked increased level of aminotransferase, which sometimes leads to misdiagnose those as liver disease caused by viral hepatitis, ischemia, and drug toxicity. The aim of this study is to investigate the clinicopathologic features of patients with CBD stones with the high level of aminotransferase in serum.


Eligibility Criteria:
Inclusion Criteria:

1. patients were diagnosed with CBD stone under endoscopic retrograde cholangiopancreatography (ERCP)
2. patients showing above 400 IU/L of aminotransferase when at the first admitted into hospital and the control groups is the patients displaying normal AST and ALT.

Exclusion Criteria:

* 1. underlying hepatobiliary disease 2. alcoholics 3. cholangitis
Safety and Effect of Doxycycline in Patients With Amyloidosis

The tetracycline antibiotic doxycycline disrupts A beta amyloid fibrils (AB) in Alzheimer's disease, transthyretin (ATTR) amyloid fibrils in familial amyloidotic polyneuropathy, and immunoglobulin light chain (AL) amyloid fibrils in transgenic mouse models of disease. If untreated, amyloid deposits impair organ function, affecting the morbidity and mortality of patients.

This single-center, twelve-month, open-label, prospective, pilot phase II study aims to determine whether doxycycline reduces amyloid deposits and improves organ function in patients with systemic or localized amyloidosis.

The investigators plan to enroll patients with measurable amyloid disease according to internationally-accepted diagnostic criteria. Patients must have stable organ function at enrollment. Eligible subjects not receiving active treatments for amyloidosis affecting their kidneys, heart, aerodigestive tracts, peripheral or autonomic nervous system(s), lungs, eyes, skin, bladder, or breasts will undergo evaluations at baseline, 6 months, and 12 months - or more frequently as clinically indicated.

Over 45 years experience indicates doxycycline is a safe, well tolerated antibiotic. The investigators will use standard grading systems to assess doxycycline response following twelve months of treatment.

In transgenic animal models of disease, the tetracycline antibiotic doxycycline disrupts A beta amyloid fibrils (AB) in Alzheimer's disease, transthyretin (ATTR) amyloid fibrils in familial amyloidotic polyneuropathy, and immunoglobulin light chain (AL) amyloid fibrils.

The aim of this single-center, 12-month open label, prospective phase II study was to determine a) the safety and tolerability of prolonged full dose doxycycline in patients with amyloidosis, and b) the effect of doxycycline treatment on amyloid-induced organ dysfunction.

We enrolled 25 patients with measurable organ dysfunction caused by amyloid deposition who were not receiving active treatment to control their amyloid production. All 25 subjects received doxycycline 100 mg by both twice daily for up to 12 months depending on their tolerance of the antibiotic. The primary endpoint, defined by the organ most affected by amyloid, was measured at baseline, 6 and 12 months along with safety laboratory values.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 or older
* Biopsy-proven amyloidosis
* Biochemical or clinical evidence of amyloid induced end-organ dysfunction

Exclusion Criteria:

* Concurrent use of other tetracyclines
* Ongoing active treatment for amyloidosis
* Pregnancy or unwillingness to use contraception by women of childbearing age
* Doxycycline drug allergy/hypersensitivity
* ECOG performance status \> 3
* NYHA class \> 3
* Renal insufficiency (estimated creatinine clearance \< 25 ml/min)
* Transaminitis (AST or ALT \> 5 times upper limit of normal)
* Diabetes mellitus or hemoglobin A1C \> 6.2%
Real-time Ultrasound-guided Paramedian Epidural Access: Evaluation of a Novel In-plane Transverse View Technique

The aim of this study is to demonstrate the feasibility of a new technique using real time ultrasound guided paramedian approach to the epidural space. This approach will use transverse view of the spine utilizing curvilinear low frequency ultrasound probe "Sonosite S nerve" and echogenic 17G tuohy needles " Pajunk TuohySono"

The investigators believe that this new technique is helpful to get the best anatomic landmark for epidural catheter placement using the real-time ultrasound.

Measurable outcomes:

* Block performance time.
* Block success rate.
* Needle Depth to epidural space

Block success rate will be measured as the rate of cases that will have successful insertion of the epidural catheter using ultrasound guidance and the case is done completely under epidural anesthesia.

All cases that will be converted to general anesthesia will be counted unsuccessful.

Other measurable outcome data that will be collected will include needle depth to the epidural space, and ultrasound measured depth to the lamina


Eligibility Criteria:
Inclusion Criteria:

* Adult Patients 30 to 80 years old at time of surgery.
* Patients in whom epidural anesthesia is planned to be used as the for surgery " Surgical epidural"

Exclusion Criteria:

* Current or recent drug abuse (within past 6 months).
* Allergy to local anesthetics
* Patient refusal.
Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)

Paroxysmal nocturnal hemoglobinuria is an acquired chronic hemolytic anemia,this study is designed to evaluate the safety and efficacy of Levamisole combined with cyclosporine A in patients with Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the setting of another bone marrow failure syndromes

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder of the hematopoietic stem cell characterized by intravascular hemolysis, hemoglobinuria, anemia, and thrombosis, Patients may be at high risk of thrombosis and may develop bone marrow failure or aplastic anemia, with low white blood cell and platelet counts,because the manifestation and pathologic processes are complicate,the treatment is very difficult,this study is designed to evaluate the safety and efficacy of Levamisole combined with cyclosporine A in patients with Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the setting of another bone marrow failure syndromes

Eligibility Criteria:
Inclusion Criteria:

1. Clinical and biochemical signs of Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the setting of another bone marrow failure syndromes
2. Diagnosis confirmed by Ham's test or Flow cytometry Patients have any Flow cytometry data
3. patient should complete levamisole study for at least half a year

Exclusion Criteria:

1. Active infection which requires antibiotic treatment
2. Pregnant or lactating women
3. Epilepsy and mental illness
4. Kidney and liver function abnormal
Emergency Versus Elective Cholecystectomy in Acute Cholecystitis in the Era of Laparoscopy.

The aim of study is compare outcome of patients undergoing early laparoscopic cholecystectomy within 72 hours from the begging of symptoms to those of patients managed conservatively and operated late after 6-8weeks after the inflammatory reaction has subsided.

Acute cholecystitis is considered one of the most common acute surgical problems. It includes typical symptoms of pain in right hypochondrium, fever, increased leucocytes count and abdominal US used to confirm this clinical diagnosis. Laparoscopic cholecystectomy (LC) is the standard treatment for acute cholecystitis due to the advantages of small wounds, less use of abdominal drains , less need for antibiotics and analgesics and less postoperative hospital stay time.Laparoscopic cholecystectomy in acute cholecystitis may be performed as soon as begging of the symptoms called emergency or urgent laparoscopic cholecystectomy and maybe scheduled in advance after controlling acute attack after 6-8weeks called elective laparoscopic cholecystectomy . Emergency laparoscopic cholecystectomy has advantage of a decreased hospital stay and avoids the risk of emergency admission for non-resolved or recurrent symptoms, which is associated with an increase in morbidity, pain and delayed return to work. Also, some trials showed increased morbidity with elective laparoscopic cholecystectomy mostly due to biliary disease while patients await surgery. Comparative studies are deficient in evaluation of outcomes of emergency cholecystectomy and elective cholecystectomy in acute cholecystitis. So the interest of our study is to compare between the emergency laparoscopic cholecystectomy and elective laparoscopic cholecystectomy regarding the feasibility and the safety of the first.

Eligibility Criteria:
Inclusion Criteria:

1. age less than 70 years.
2. fit for surgery.

Exclusion Criteria:

1. patients with co-existent common bile duct stones based on imaging and biochemical criteria.
2. Patients with Pancreatitis .
3. Patients with previous upper abdominal surgery.
4. Significant medical disease rendering patient unfit for Laparoscopic surgery (e.g.Chronic Pulmonary Disease, significant Cardiac Disease)
Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain

The aim of the study is to assess the efficacy of Buscopan® (hyoscine butylbromide) in comparison to 654-II (anisodamine)in acute gastric or intestinal spasm-like pain.


Eligibility Criteria:
Inclusion criteria:

1. Patients must sign and date an Informed Consent consistent with International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) guidelines and local regulation prior to participation in the trial.
2. Patients must agree to cooperate with all trial evaluations and perform all required tasks.
3. Patients with acute gastric or intestinal spasm-like pain (without severe vomiting and surgical acute abdomen).
4. Male or female patients aged 18 to 70 years.
5. The pain intensity upon screening is at least point 6 on a 0-10 numerical rating scale (NRS).

Exclusion criteria:

1. Patients with the following concomitant disease is not eligible for enrollment:

   * Painful gastric or intestinal spasm of organic origin such as Crohn's disease, ulcerative colitis, lactose intolerance, gastrointestinal perforation, suspected gastrointestinal perforation or peritoneal effusion.
   * Pain related with malignancy.
   * Patients with other severe pain states of organic origin.
   * Mechanical stenosis of the gastrointestinal tract ,megacolin.
   * Urinary retention associated with mechanical stenosis of urinary tract.
   * Narrow-angled glaucoma.
   * Tachyarrhythmia.
   * Myasthenia gravis.
   * Meulengracht-Gilbert syndrome.
   * Known depression or known mental illness, anxiety disturbance.
2. Patients taking the following concomitant medication within 7 half-life of concomitant medication (the duration from taking concomitant medication to attending the trial is less than 7 half-life) are not eligible for enrollment:

   * Analgesics,
   * Spasmolytics,
   * Anticholinergics
   * Affecting gastrointestinal motility, such as propantheline, metoclopramide, cisapride, loperamide, diphenoxylate, opioid analgesics, antacids and other ulcer treatment
   * Regular administration of laxatives
   * Narcotics
   * Antidepressant treatment or treatment with psychoactive drugs
3. Pregnancy and/or lactation or planned pregnancy;
4. Known hypersensitivity to N-butylscopolammonium bromide
5. Alcohol, or drug abuse.
6. Simultaneous participating in another clinical trial, or discontinuing from another clinical trial before randomization (administration of study medication); moreover, in the case of screening failure or premature discontinuing from the trial, repeated enrollment is forbidden.
7. Unwilling to or unable to complete the entire trial procedure according to the protocol.
8. In investigator's opinion, the patient is not proper for the trial.
Compensatory Reserve Index (CRI) for Management of COVID-19

The FDA has approved the CipherOx CRI T1 Tablet for use in subjects aged 19-36, and that this study aims to evaluate the device in subjects aged outside of this range and is being used off label.

The FDA determined the Cipher OX CRI T1 Tablet to be a class II device in 2016, and additional research has been done since the FDA determination to further support the use of the device outside of its current labeling.


Eligibility Criteria:
Inclusion Criteria:

Eligible patients will be those who are:

* COVID-19 positive;
* Ages \> 18 and \< 70 years old;
* Require \> 2 liters of oxygen by nasal cannula to maintain SpO2 \> 90%;
* Are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service).

Exclusion Criteria:

* COVID-19 negative
* Age \<18 or \>70 years
* On \<2 liters oxygen via nasal canula
* Pregnant
* Incarcerated
* DNR/DNI
* Decisionally Challenged
Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates

Outbreaks of skin and soft tissue infections (SSTI) related to community associated Methicillin-resistant Staphylococcus aureus (MRSA) have become increasingly common in military training units. Risk factors for MRSA related SSTI such as crowding, poor hygiene and shared equipment are often hard to avoid in a military training environment, often designed to simulate battlefield conditions.

It has recently been demonstrated that military recruits colonized with MRSA may be at increased risk of developing SSTI. Studies in the hospital environment have shown that decolonizing inpatients known to carry MRSA decreases the rates of MRSA related infections in the treated individuals and also in their inpatient unit as a whole.

The investigators propose a randomized, double blind, placebo controlled trial to:

1. Evaluate the effectiveness, feasibility, and safety of chlorhexidine body cloths, self-administered three times weekly, in preventing SSTI among recruits in military training facilities; and
2. Evaluate the effectiveness of chlorhexidine body cloths in decreasing rates of Staphylococcus aureus colonization among military recruits.


Eligibility Criteria:
Inclusion Criteria:

* Enrolled in US Marine Officer Candidates School
* Age 18-35 years
* Provide documented informed consent and HIPAA authorization

Exclusion Criteria:

* Is currently taking oral antibiotics and will continue to take antibiotics during the study (such as antibiotics used to treat acne)
* Has a known or suspected allergy or intolerance to chlorhexidine (Hibistat, Hibiclens)
* Is currently using certain skin products and is uninterested in stopping use of the products during the study
* Pregnant or breastfeeding
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).


Eligibility Criteria:
Inclusion Criteria:

* Biopsy proven new world cutaneous or mucocutaneous leishmania

Exclusion Criteria:

* Prolonged QT
* Liver disease
* Pancreatitis